Author/Authors :
Sistanizad, Mohammad Department of Clinical Pharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences - Department of Clinical Pharmacy - Faculty of Pharmacy - Shahid Beheshti University of Medical Sciences, Tehran , Azizi, Ebrahim Molecular Research Lab - Department of Pharmacology and Toxicology - Faculty of Pharmacy - Tehran University of Medical Sciences , Khalili, Hosein Department of Clinical Pharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences , Hajiabdolbaghi, Mahboobeh Department of Infectious Disease - Faculty of Medicine - Tehran University of Medical Sciences , Gholami, Kheirollah Department of Clinical Pharmacy - Faculty of Pharmacy - Tehran University of Medical Sciences , Mahjub, Reza Department of Pharmaceutics - Faculty of Pharmacy - Tehran University of Medical Sciences, Tehran
Abstract :
The aim of this study was to determine the association of n-acetyltransferase-2 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in Iranian pulmonary tuberculosis patients. Acetylating phenotypes was studied in 50 Iranian pulmonary tuberculosis patients using metabolic ratio of plasma acetyl-Isoniazid to Isoniazid. The association between hepatotoxicity and the n-acetyltransferase-2 phenotype was evaluated by using the chi-square (x2) test. The metabolic ratio had a bimodal distribution with an antimode value of 1.0. Based on the metabolic ratio of the mentioned patients, 20 (40%) were slow acetylators and 30 (60%) were fast ones. Hepatotoxicity was manifested in 9 of 20 slow acetylators (45%) and only in 5 of 30 rapid acetylators (16.7%). There was a significant difference in the frequency of hepatotoxicity between the slow and fast acetylators (x2 = 4.778, and p = 0.03). Sex and age were not found to be risk factors for hepatotoxicity. Our findings show that slow acetylation profile is significantly associated with a higher risk of developing hepatotoxicity due to the anti-TB drugs in Iranian pulmonary tuberculosis patients.
Keywords :
Antituberculosis , Tuberculosis , Polymorphism , Isoniazid , Hepatotoxicity